|Go to market news section|
For immediate release
28 July 2017
MedicX Fund Limited
("MedicX Fund", "the Fund" or "the Company")
Notice of dividend
The Directors have approved a quarterly dividend of 1.5p per Ordinary Share in respect of the period 31 March 2017 to 30 June 2017. The Directors expect, subject to unforeseen circumstances, to pay dividends totalling 6.0p per Ordinary Share in respect of the financial year ending 30 September 2017. The dividend will be paid on 28 September 2017 to ordinary shareholders on the register as at 18 August 2017 (the "Record Date"). The corresponding ex-dividend date will be 17 August 2017.
The dividend payable on 28 September will be made in advance of the Company submitting a REIT notice to HMRC seeking entry into the UK REIT regime. As announced on 15 March 2017 the application for entry into the UK REIT regime remains subject to shareholders approval at an EGM expected in early September 2017.
The Company is offering qualifying shareholders the opportunity to take new ordinary shares in the Company, credited as fully paid, in lieu of the cash dividend to be paid on 28 September 2017, by participating in the Scrip Dividend Scheme (the "Scheme") previously put in place by the Company on 5 May 2010.
The option to participate will be available to shareholders until 7 September 2017 (the "election date"). Further information on the Scheme, together with a copy of the Scheme Document (which contains the terms and conditions of the Scheme) and relevant mandate form document, is available for inspection at the National Storage Mechanism (http://www.morningstar.co.uk/uk/nsm), or through the Scrip Dividend portal on the Company's website (http://www.medicxfund.com/scrip).
For further information please contact:
MedicX Fund +44 (0) 1481 723 450
David Staples, Chairman
Octopus Healthcare Group +44 (0) 20 3142 4820
Mike Adams, Chief Executive Officer
Canaccord Genuity +44 (0) 20 7523 8000
Andrew Zychowski/Helen Goldsmith
Buchanan +44 (0) 20 7466 5000
Charles Ryland/Victoria Hayns
Information on MedicX Fund Limited
MedicX Fund Limited ("MXF", the "Fund" or the "Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom, listed on the London Stock Exchange, with a portfolio comprising 157 properties.
The Investment Adviser to the Company is Octopus Healthcare Adviser Ltd, which is part of the Octopus Healthcare group. Octopus Healthcare invests in and develops properties as well as creating partnerships to deliver innovative healthcare buildings to improve the health, wealth and wellbeing of the UK. It currently manages over £1 billion of healthcare investments across a number of platforms, with a focus on five core areas: GP surgeries, care homes, special education schools, retirement housing and private hospitals. Octopus Healthcare is part of the Octopus group, a fast-growing UK fund management business with leading positions in several specialist sectors including healthcare property, energy, property finance and smaller company investing. Octopus manages £6 billion of funds for more than 50,000 retail and institutional investors.
Octopus Healthcare Adviser Ltd is authorised and regulated by the Financial Conduct Authority.
The Company's website address is www.medicxfund.com. Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website), nor the contents of any website accessible from hyperlinks within this announcement, are incorporated into, or forms part of, this announcement.
The Company's Legal Entity Identifier is 2138008POF35FTNFCB25.
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.
|©London Stock Exchange plc. All rights reserved|